Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety

  • Eur J Med Chem. 2018 May 10;151:1-8. doi: 10.1016/j.ejmech.2018.03.060.
Kai Lv  1 ,  Zeyu Tao  1 ,  Qian Liu  2 ,  Lu Yang  1 ,  Bin Wang  3 ,  Shuo Wu  1 ,  Apeng Wang  1 ,  Menghao Huang  4 ,  Mingliang Liu  5 ,  Yu Lu  6
Affiliations
  • 1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
  • 2. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China; Institute of Molecular Design and Synthesis, School of Pharmaceutical Science & Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin, 300072, China.
  • 3. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
  • 4. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indiana, 46202, USA.
  • 5. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. Electronic address: [email protected].
  • 6. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China. Electronic address: [email protected].
PMID: 29601990 DOI: 10.1016/j.ejmech.2018.03.060
Abstract

We herein report the design and synthesis of benzothiazinones containing a piperidine moiety as new antitubercular agents based on the structure feature of IMB-ZR-1 discovered in our lab. Some of them were found to have good in vitro activity (MIC < 1 μg/mL) against drug-susceptible Mycobacterium tuberculosis H37RV strain. After two set of modifications, compound 2i were found to display comparable in vitro anti-TB activity (MIC < 0.016 μg/mL) to PBTZ169 against drug-sensitive and resistant mycobacterium tuberculosis strains. Compound 2i also showed acceptable PK profiles. Studies to determine PK profiles in lung and in vivo efficacy of 2i are currently under way.

Keywords
Antimycobacterial activity; Benzothiazionones; PBTZ169; Synthesis.
Products